Currencies:
RUB/BRL 0,0932
0,0006
RUB/INR 1,4092
0,01
RUB/CNY 0,1209
0,0009
RUB/ZAR 0,2893
0,0024
BRL/RUB 10,7503
0,0157
BRL/INR 15,1489
0,0221
BRL/CNY 1,2997
0,0017
BRL/ZAR 3,1086
0,002
INR/RUB 0,7096
0,0014
INR/CNY 0,0858
0,0001
INR/ZAR 0,2052
0,0002
INR/BRL 0,066
0,0001
ZAR/BRL 0,3219
0,0004
ZAR/RUB 3,4551
0,0039
ZAR/INR 4,8689
0,0056
ZAR/CNY 0,4177
0,0004
CNY/RUB 8,2715
0,0012
CNY/INR 11,656
0,0018
CNY/BRL 0,769
0,0014
CNY/ZAR 2,392
0,0014
Moscow 23 °C
Brazilia 17 °C
New Delhi 27 °C
Beijing 36 °C
Pretoria 9 °C

07:00 BRICSINFORM

BRICSINFORM
07:00

BRICSINFORM

We are making reports on the most important events from the scene, from exhibitions and premieres, f...

16+

07:15 Check List

07:15

Check List

The bays of Sakhalin, the endless steppes of Elista, thousands of lakes in Altai and much more in th...

16+
BRICSINFORM

TV BRICS PROJECTS

11.08.2211:27 Society
Journalists' Union of Russia contest for the best journalistic work summed up
08.08.2209:58 Culture
TV BRICS will hold a telethon for Indian Independence Day
04.08.2211:37 Society
TV BRICS International Media Network to premiere "Vmeste-RF" programme in South Africa
India
28.06.22 16:45
Society

India's first mRNA COVID-19 vaccine to get Emergency Use Authorisation

Phase 2 and phase 3 data trials were conducted on 4000 participants to evaluate vaccine safety

The Subject Expert Committee (SEC) in a meeting held on Friday recommended Emergency Use Authorisation (EUA) for India's first mRNA COVID-19 vaccine, sources told ANI on Tuesday. The Drugs controller general of India (DCGI) is expected to give Emergency Use Authorisation to Gennova's mRNA vaccine any time soon.

The SEC under India's drug regulator found data submitted by Gennova Biopharmaceuticals satisfactory in the Friday meeting, people in the know told ANI.

The company submitted data in April and provided additional data in May.

Earlier in May, Gennova had released a statement to ANI regarding updates on submitting phase 3 data.

"Gennova is in communications with the regulatory agency and submitting all necessary data and information required for the product approval," said Gennova's spokesperson.

"Product development using innovative technologies like mRNA, a fourth-generation vaccine platform stable at 2 to 8 degrees Celcius, is a challenging journey during pandemic times," the spokesperson further said.

The company has conducted phase 2 and phase 3 data trials on 4000 participants to evaluate vaccine safety, immunogenicity and tolerability.

The vaccine - GEMCOVAC-19 - is the country's first homegrown mRNA COVID- 19 vaccine and is seen as a game-changer for the healthcare industry, as reported by ANI, a partner of TV BRICS.

Оцените материал

MORE ON THE TOPIC

14.08.2220:00 Society
BRICS News Digest for the previous week
13.08.2210:23 Society
Brazil continues mass vaccination against COVID-19
12.08.2214:22 Society
Russian Foreign Ministry: BRICS countries discuss principles of alliance expansion
12.08.2211:21 Society
South Africa and India are becoming popular tourist destinations for Russians
12.08.2209:25 Society
Shenzhen constructs more than 30 railway and expressway routes to neighboring cities
11.08.2211:27 Society
Journalists' Union of Russia contest for the best journalistic work summed up